Skip to main content

Market Overview

Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma

Share:

In a report published Friday, Wedbush Securities analyst David M. Nierengarten reiterated an Outperform rating and $111.00 price target on Synageva Biopharma Corp. (NASDAQ: GEVA).

In the report, Wedbush Securities noted, "GEVA reported Q4:14 EPS of ($1.73), slightly below our estimate of ($1.67) and consensus of ($1.71). The company ended the quarter with $447M in cash and cash equivalents, not including proceeds from the recent follow-on offering of $309M, and guided towards 2015 total operating expenses of between $280M and $295M. We had previously estimated operating expenses to be approximately $240M, with the increase likely reflecting additional investment in Kanuma's launch later this year, in part by focusing on patient identification programs."

Synageva Biopharma closed on Thursday at $99.42.

Latest Ratings for GEVA

DateFirmActionFromTo
May 2015BairdDowngradesOutperformNeutral
Mar 2015JP MorganDowngradesOverweightNeutral
Feb 2015CitigroupMaintainsNeutral

View More Analyst Ratings for GEVA

View the Latest Analyst Ratings

 

Related Articles (GEVA)

View Comments and Join the Discussion!

Posted-In: David M. Nierengarten Wedbush SecuritiesAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com